Quarterly news on Health Issues from the OECD, including recent work on value in pharmaceutical pricing and on public health and genomics, as well as recent articles and events on health from the OECD, and information on forthcoming publications such as Health at Glance 2013 and the latest publication on Cancer Care, Working papers on Managing hospital volumes, alcohol consumption and the role of fiscal policies in health promotion.
In Portugal, health spending has been reduced from 10.8% of GDP in 2009 to 10.2% now. This has been achieved by rationalising spending on pharmaceuticals, promoting the use of generic drugs, moderating salaries; cutting the fees paid to hospitals, and increasing user charges, while still protecting those in most need, said OECD Secretary-General.
This document outlines the methodologies and tools currently used to assess the risk of chemicals to children’s health and also identifies possible needs for additional guidance or tools based on the results of an on-line survey conducted in November 2011. The following areas of risk assessment are covered: definitions, hazard and exposure assessment, risk characterisation, cohort studies and combined exposure to multiple chemicals.
OECD Newsletter on Employment, Migration, Health and Social Affairs - Autumn 2014
English, PDF, 108kb
The future of public health: policy decisions today for tomorrow’s populations. Our health, our economy, our society, our future: a Brave New World. Remarks by Yves Leterme, Deputy Secretary-General, OECD. Brussels, Belgium, September 4th 2013.
English, PDF, 1,992kb
Governments have a fiscal and social responsibility to ensure that limited research and development resources are used wisely and cost-effectively in support of social, economic, and scientific aspirations. Countries that wish to promote the continued responsible development of nanotechnology will, however, need quantitative data on the economic impact of nanotechnology to guide further investment and policy decisions.
This book discusses scientific and technological tools at the centre of a renewed interest in marine biotechnology that is contributing to a new bioeconomy sector in many countries and offering potential new solutions to global challenges.
This report presents the findings of a research project to investigate the drivers and criteria shaping the application of genomic biotechnology to health in different national settings, and the barriers to implementation nationally and internationally. Findings are based on case studies on Finland, Israel, Luxembourg, Mexico, the United Kingdom, China and South Africa.
English, PDF, 1,115kb
Experience from the substantial health gains of the 20th century suggests that spending on prevention could be an important factor. Therefore, gathering data on such spending that are consistent and comparable, both over time and across countries, is potentially very useful. This paper aims to help clarify what should be included as spending on prevention under SHA 2011 to facilitate accurate comparisons.
Belgium has a good record in delivering accessible care, but adaptation to population ageing will be complicated by the fragmentation of responsibilities in the healthcare system and a strong reliance on government regulations.